| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Medicine Branch, Division of Cancer Treatment, Clinical Oncology Program, National Cancer Institute, Bethesda, Maryland 20205
We have partially purified human estrogen receptor from MCF-7 breast cancer cells in order to further characterize the chemical and biological properties of the receptor and to prepare specific receptor antibodies for radioimmunoassay. The estrogen receptor from MCF-7 cell cytosol was purified 1,166-fold (27% recovery) over starting cytosol by combining ammonium sulfate precipitation, affinity chromatography, and Sephadex G-100 gel filtration. The affinity resin consisted of estrone 17-(O-carboxymethyl)oxime:bovine serum albumin: Sepharose 4B. Under high salt conditions, the molecular weight of the purified receptor is 50,000 and is identical to that obtained on chromatography of crude cytosol. Sucrose density gradient centrifugation also revealed the purified receptor sedimenting at the same position as the crude cytosol receptor. The following methods to purify crude cytosol estrogen receptors are much less effective. (a) With DNA-cellulose chromatography, KCl elution revealed peaks at 0.04 M KCl (11-fold purification) and 0.22 M KCl (12.5-fold purification). This could not be combined sequentially with affinity chromatography because high salt conditions were required for affinity elution, and removal of salt by dialysis caused the receptor to adhere to the tubing. (b) With hydroxylapatite chromatography, phosphate elution revealed peaks at 0.12 M phosphate (1.1-fold purification) and 0.175 M phosphate (1.1-fold purification). (c) With phosphocellulose chromatography, KCl elution revealed only one peak at 0.18 M KCl (1.6-fold purification). (d) With diethylaminoethyl cellulose chromatography, KCl elution revealed 4 peaks at 0.025 M (1-fold purification), 0.12 M (1.27-fold purification), 0.14 M (1.28-fold purification), and 0.2 M (0.36-fold purification).
1 To whom requests for reprints should be addressed, at Building 10, Room 6B02, Medicine Branch, National Cancer Institute, NIH, Bethesda, Md. 20205.
Received 10/ 1/79. Accepted 6/ 2/80.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |